A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes ypN1mi, ypN1-3 After Neoadjuvant Chemotherapy

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT02954874

Study #:
STUDY00140733

Start Date:
Apr 12, 2017

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02954874

View Complete Trial Details & Eligibility at ClinicalTrials.gov